.png)
.png)
University of Oxford spin-out revealed as winner of ‘Golden Ticket’ programme for planetary health innovations
University of Oxford spin-out HydRegen has been revealed as the winner of a programme designed to recognise innovations in planetary health created by Pioneer Group in partnership with CPI.
Investing in life science – learnings from the first round of investments from Discovery Park Ventures
Launched in May 2022 by thriving life science community Discovery Park, Discovery Park Ventures (DPV) is an investment fund that invests in ambitious and growing life sciences companies, driving disruptive innovation and catalysing economic growth. Initially a £1 million fund, DPV has now expanded to £3 million.
AI in life sciences: future-proofing strategies
In the final piece of the 'AI in life sciences' series, Jenny Yu, Marsh’s Life Sciences industry practice leader and experts from law firm Kennedys emphasize essential steps for life sciences companies to develop and implement a successful AI business strategy. They delve into effective management of outcomes from AI technologies and strategies to mitigate potential risks.
CEO Update - 15 April 2024
In case you missed it last week, post-Brexit border paperwork and inspections have been postponed for the life sciences sector, thanks to BIA work. Importers of laboratory reagents and materials used in the manufacture of medicines in the UK’s life sciences sector have been given a six-month extension to make the necessary changes to their supply chains for new post-Brexit border paperwork and border inspections.
CHAIN Biotech collaborates with German Cancer Research Center on development of a novel oncology vaccine
CHAIN Biotechnology Ltd and the German Cancer Research Center (DKFZ) have signed an agreement to collaborate on the development of therapeutic cancer vaccines for indications caused by Human Papillomavirus (HPV).
Macomics unveils its lead first-in-class anti-pan-LILRB monoclonal antibody programme with positive pre-clinical data
Macomics’ lead programme, MACO-355, in IND enabling studies is a ligand-blocking independent pan-LILR monoclonal antibody for the treatment of cancer.
Coulter Partners top hires for VC & PE portfolio companies Q1-2024
Recent top global hires for Venture Capital and Private Equity portfolio companies, covering a broad range of disciplines and sectors across Life Sciences, Health and Tech.
Post-Brexit border paperwork and inspections postponed for life sciences sector
Importers of laboratory reagents and materials used in the manufacture of medicines in the UK’s life sciences sector have been given a six-month extension to make the necessary changes to their supply chains for new post-Brexit border paperwork and border inspections.
Abzena announces major investment in bioconjugation and ADC capabilities in response to increasing industry demand
Abzena announced a significant expansion of their Bristol, PA bioconjugate development and cGMP manufacturing site. The $5 million investment in expanded laboratory space, new equipment, and facility upgrades, builds upon the site’s existing bioconjugation capabilities and increases capacity to support the delivery of fully integrated biopharmaceutical drug programs.
CEO Update - 8 April 2024
I don’t always start Newscast with a technical detail – but this one matters and underpins the work of many, many companies in our Association. In short, keep doing your experiments and manufacturing medicines as normal as we work hard to keep your reagents and materials supply chain operating smoothly.